The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.
Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.
California's new proposed psychedelics "decriminalization" would, in fact, LEGALIZE possession of many psychedelic substances.
MINDCURE's R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.
ATAI Life Sciences is set to become the new industry leader among psychedelic stocks. But it may not be the best OPPORTUNITY for investors when trading begins.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now